Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 9/20 | 0.38 |
| ▸ | CASP1 | P29466 | 5/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 5/20 | 0.37 |
| ▸ | CASP3 | P42574 | 5/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.35 |
| ▸ | CASP6 | P55212 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158934 | 0.82 | MME (0.44) | CASP1CASP8CASP3MMEACE | |
| SCHEMBL646016 | 0.79 | CASP1 (0.58) | CASP1CASP8CASP3MMEACE | |
| SCHEMBL26236631 | 0.79 | CASP1 (0.58) | CASP1CASP8CASP3MMEACE | |
| SCHEMBL6161334 | 0.78 | MME (0.34) | XIAPMMEACE | |
| SCHEMBL7668008 | 0.74 | CASP3 (0.43) | CASP1CASP8CASP3 | |
| SCHEMBL645040 | 0.74 | CASP1 (0.59) | CASP1CASP8CASP3MMEACE | |
| SCHEMBL13140297 | 0.73 | CASP1 (0.55) | XIAPCASP1CASP8CASP3 | |
| SCHEMBL644895 | 0.73 | CASP1 (0.55) | XIAPCASP1CASP8CASP3 | |
| SCHEMBL10249335 | 0.73 | CASP1 (0.55) | XIAPCASP1CASP8CASP3 | |
| SCHEMBL6158985 | 0.72 | CASP1 (0.46) | CASP1CASP3MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1062210-B1 | 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | VERTEX PHARMA (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6426413-B1 | SUCH AS (N-BENZYLOXYCARBONYL-HYDRAZINO)-ACETIC ACID TERT-BUTYL ESTER; FOR PREVENTING AND TREATING INTERLEUKIN-MEDIATED DISEASES, APOPTOSIS, AUTOIMMUNE DISEASES, BONE DISORDERS, PROLIFERATIVE DISORDERS, INFECTIONS, AND DEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-30 | — | — | US | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| EP-1062210-A1 | 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046248-A1 | 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | XIAP 1465/4885CASP1 847/4885CASP8 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.